---
category: markets
content_type: brief
date: '2026-03-25T11:40:49.591477+00:00'
entities:
- name: Merck
  type: organization
- name: Terns Pharmaceuticals
  type: organization
- name: leukemia
  type: disease
impact: high
reporter: gemini-flash
sentiment: neutral
slug: merck-to-acquire-terns-pharmaceuticals-for-67-billion-to-bolster-cancer-drug-pip
sources:
- feed: marketwatch-top
  title: Merck makes a big move into new cancer treatments with a $6.7 billion buyout
    deal
  url: https://www.marketwatch.com/story/merck-makes-a-big-move-into-new-cancer-treatments-with-a-6-7-billion-buyout-deal-5f3475ec?mod=mw_rss_topstories
subcategory: mergers-and-acquisitions
summary: Merck has announced a $6.7 billion agreement to acquire Terns Pharmaceuticals,
  a company focused on developing novel cancer therapies, including an oral treatment
  for leukemia.
tags:
- mergers and acquisitions
- pharmaceuticals
- oncology
- leukemia
- drug development
title: Merck to Acquire Terns Pharmaceuticals for $6.7 Billion to Bolster Cancer Drug
  Pipeline
---

Merck announced on Tuesday that it has entered into a definitive agreement to acquire Terns Pharmaceuticals for approximately $6.7 billion. The deal aims to enhance Merck's oncology portfolio by integrating Terns Pharmaceuticals' pipeline of cancer treatments.

Terns Pharmaceuticals is known for its work on novel therapeutics, including a potential oral therapy for leukemia. This acquisition signals Merck's strategic intent to expand its offerings in the competitive landscape of cancer drug development. The transaction is expected to close in the second half of 2024, subject to customary closing conditions, including regulatory approvals.

## Key Takeaways
*   Merck is acquiring Terns Pharmaceuticals for $6.7 billion.
*   The deal includes Terns Pharmaceuticals' pipeline, notably an oral leukemia treatment.
*   The acquisition is expected to close in the second half of 2024.

---
*This article was generated by an AI reporter based on the sources listed above.*